Redundant by Design: How Overlapping R&D Across Business Units Quietly Erodes Portfolio Value

There is a particular kind of inefficiency that thrives inside well-intentioned corporate structures—one that rarely appears on an executive dashboard but consistently undermines shareholder returns. It emerges not from poor strategy or bad management, but from a fundamental misalignment between how holding companies are organized and how innovation actually works across a diversified portfolio.

When two or more business units within the same enterprise independently develop solutions to the same underlying problem, every dollar invested in the second effort is, at minimum, partially wasted. Multiply that dynamic across a portfolio of five, ten, or fifteen subsidiaries, and the cumulative cost can easily reach tens of millions of dollars annually—capital that could have funded genuine competitive advantages instead.

This is the hidden cost of parallel innovation, and it deserves far more attention than it typically receives.

Why Parallel Development Happens in the First Place

The root cause is rarely negligence. More often, it is the natural byproduct of a governance model that prizes subsidiary autonomy. When a holding company grants its business units the freedom to operate independently—setting their own product roadmaps, managing their own technology stacks, and building their own internal capabilities—it is usually doing so with good reason. Autonomy accelerates decision-making, preserves entrepreneurial culture, and allows each unit to remain responsive to its specific market.

But autonomy without visibility creates silos. And silos create redundancy.

A logistics subsidiary invests in a custom route-optimization engine. Meanwhile, a supply chain unit three divisions over has been building nearly identical functionality for eighteen months. Neither team knows the other exists. Both present their projects to separate boards. Both receive funding. Both eventually deliver a working product—at roughly twice the combined cost a single coordinated effort would have required.

This scenario is not hypothetical. It plays out across American holding companies with remarkable regularity, particularly in areas like data infrastructure, compliance tooling, customer-facing digital platforms, and cybersecurity frameworks.

Quantifying the Blind Spot

One of the reasons parallel innovation persists is that it is genuinely difficult to see. Traditional financial reporting is organized by business unit, not by function or capability type. A duplicated investment in, say, a customer identity management system will appear as a legitimate line item in two separate capital expenditure budgets—each individually justifiable, neither flagged as redundant.

Several holding companies that have undertaken enterprise-wide capability audits have reported striking findings. In one widely referenced case from the manufacturing sector, a parent company discovered that seven of its twelve subsidiaries had independently developed proprietary quality-assurance software. The combined development cost exceeded $40 million. A single shared platform, built to accommodate the nuances of each unit, was later estimated to have cost less than $9 million.

The math is jarring. But the more instructive detail is how long it took leadership to discover the overlap—in most cases, years.

Identifying Overlapping Investments Before They Compound

A structured approach to R&D visibility begins with what might be called a capability taxonomy: a standardized classification system that maps every active development initiative across the portfolio to a common functional category. When a holding company can view all active projects through a unified lens—regardless of which subsidiary owns them—redundancies become far easier to detect.

This is not the same as centralizing innovation. The goal is not to pull decision-making authority away from business units. It is simply to create enough transparency that leadership can identify when two teams are climbing the same mountain from different sides.

Practical mechanisms include:

• Quarterly capability registries: Each subsidiary submits a structured summary of active development projects, categorized by function and estimated investment. The parent company maintains a consolidated view.
• Cross-unit technology councils: Representatives from each business unit meet periodically to share roadmaps and surface potential overlaps before they become expensive.
• Shared services evaluation criteria: Before any subsidiary greenlit a new internal build, a brief assessment determines whether an existing solution within the portfolio could be adapted or licensed at lower cost.

None of these mechanisms require a subsidiary to surrender control of its product direction. They simply introduce a layer of coordination that most holding companies currently lack.

Coordination Without Stifling Innovation

The legitimate concern among subsidiary leaders is that portfolio-level R&D oversight will slow them down—that every new initiative will require approval from a central committee, or that shared platforms will be too generic to serve their specific needs effectively.

This concern is worth taking seriously, because it reflects a real risk. Poorly designed coordination mechanisms can absolutely become bureaucratic bottlenecks. The antidote is not less coordination, but smarter coordination.

The most effective holding companies draw a clear distinction between core capabilities—the foundational systems and infrastructure that all subsidiaries depend on—and differentiated capabilities, the proprietary innovations that give each business unit its competitive edge. Coordination is applied aggressively to the former and deliberately withheld from the latter.

A shared data warehouse is a core capability. A proprietary pricing algorithm developed by a specific subsidiary is a differentiated capability. Conflating the two is where most coordination efforts go wrong.

When subsidiaries understand that the parent company is not interested in standardizing what makes them distinctive—only in eliminating the redundant plumbing underneath—resistance tends to diminish substantially.

The Compounding Return on Coordination

The financial case for R&D coordination extends beyond eliminating waste. When a holding company successfully consolidates overlapping capabilities, it often discovers that the resulting shared platform is more capable than any of the individual solutions it replaced. Pooled investment produces better outcomes than fragmented investment, almost by definition.

More significantly, intellectual property developed under a coordinated model belongs to the enterprise as a whole—creating portfolio-wide value rather than value trapped inside a single subsidiary. When that subsidiary is eventually divested, the IP either transfers with it (reducing its strategic utility to the remaining portfolio) or stays behind (potentially stranding the divested unit without capabilities it depends on). Neither outcome is optimal.

Building shared capabilities at the portfolio level from the outset avoids this dilemma entirely.

A Framework for Moving Forward

For holding companies ready to address parallel innovation systematically, the path forward involves three sequential steps.

First, establish visibility. Conduct a full audit of active R&D and product development investments across all subsidiaries. Categorize each initiative by function. Identify overlaps.

Second, rationalize the portfolio. For each identified overlap, determine whether consolidation makes sense given the relative maturity of each initiative, the degree of customization each subsidiary requires, and the political dynamics involved in migrating teams to a shared solution.

Third, institutionalize coordination. Build the ongoing mechanisms—capability registries, technology councils, shared services criteria—that prevent new redundancies from accumulating over time.

This is not a one-time exercise. Parallel innovation is a structural tendency, not a one-time mistake. The holding companies that sustain the greatest long-term value from their portfolios are those that treat R&D coordination as a permanent governance discipline rather than a periodic cleanup effort.

The capital being consumed by redundant development today is not gone—it is simply misallocated. With the right visibility and the right coordination structures, it can be redirected toward the differentiated investments that actually build lasting competitive advantage across the enterprise.